This landscape identifies 11,168 patent records published between 2015 and mid-2026 that combine isothermal amplification methods - such as recombinase polymerase amplification and loop-mediated isothermal amplification - with practical constraints like primer design, inhibitor tolerance, multiplexing and lateral-flow readout. That figure counts records, not unique inventions, so continuation filings and multiple jurisdictions for the same underlying invention are included. Because publication lags filing by around 18 months, the true count for 2025 and 2026 filings will rise as those applications continue to publish.

The ranked leaders span sequencing and diagnostics companies alongside major US academic research institutes, with the top assignee holding 450 records against 268 for the fifth-ranked and 181 for the tenth-ranked filer. The top 5 combined account for 16.8% of all 11,168 records in scope, and the top 10 combined reach 27.6% - a concentrated but not monopolised field. Several of the largest historical filers show sharp year-on-year declines in the most recent recorded year, which may reflect either genuine pullback or publication lag rather than exit from the field.

Filings peaked at 938 records in 2021 and fell to 394 by 2024, a 58% decline over that three-year span. That peak coincides with the pandemic-era surge in point-of-care diagnostic development, and the subsequent drop suggests a normalisation once emergency-driven R&D funding and regulatory urgency eased. Figures for 2025 and 2026 are still incomplete due to the typical 18-month lag between filing and publication, so the field may not be shrinking as sharply as the raw numbers for those years suggest.

The core enzymatic chemistry is heavily claimed - C12Q covers 76.4% of all 11,168 records - but adjacent classes are comparatively thin: B01L lab apparatus sits at 8.9% and C40B combinatorial libraries at just 4.2%. That gap points toward device-integration claims, such as electrical or impedance-based detection and portable temperature-control hardware, as areas with more open claim space than the core chemistry itself. Multiplexed lateral-flow readout formats also appear less densely claimed relative to the underlying amplification methods.

US20220073975A1, filed by Alveo Technologies, describes amplifying and detecting a target nucleic acid using recombinase polymerase amplification, optionally combined with a second isothermal reaction such as loop-mediated isothermal amplification, with detection based on measuring a modulated electrical signal. It is notable for moving away from optical or lateral-flow readout toward electrical detection of amplification products. Anyone designing an RPA/LAMP workflow with electrical or impedance-based detection should review this filing's specific claim language before finalising a detection architecture.